Catalyst Pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y.
- For FY21 total revenues are estimated to be approximately $141 million, an increase of roughly 18% Y/Y, better than the consensus of $138.3 million.
- Last week, Catalyst announced that the District Court Judge in its case against the FDA had issued an order granting Catalyst Summary Judgment in its action against the FDA.
- As a consequence of that order, the FDA has invalidated Jacobus Pharmaceutical Company Inc's Ruzurgi approval for pediatric patients with Lambert-Eaton myasthenic syndrome.
- The Company has ended the year with cash and investments of approximately $191 million, with no funded debt.
- Guidance: The Company forecasts FY22 sales of $195 million - $205 million, representing a 38%-45% Y/Y increase, compared to the consensus of $163.53 million.
- Price Action: CPRX shares are trading 6.04% at $5.97 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in